%0 Journal Article
%A Huntley, Dixie
%A Giménez, Estela
%A Pascual, María Jesús
%A Remigia, María José
%A Amat, Paula
%A Vázquez, Lourdes
%A Hernández Martín, Marta M.
%A Hernández Boluda, Juan Carlos
%A Gago, Beatriz
%A Piñana, José Luis
%A García, Magdalena
%A Martínez, Ariadna
%A Mateo, Eva
%A Gozalbo Rovira, Roberto
%A Albert, Eliseo
%A Solano, Carlos
%A Navarro, David
%T Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide
%D 2020
%@ 0268-3369
%@ 1476-5365
%U https://hdl.handle.net/20.500.14352/107122
%X AbstractCytomegalovirus (CMV) DNAemia and CMV disease have been reported as more frequent in patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HSCT) than in those receiving HLA-matched allografts. This could be due to impaired CMV-specific T-cell reconstitution. Here, we conducted a multicenter observationalstudy to assess CMV pp65 and IE-1-specific T cells kinetics in patients undergoing unmanipulated Haplo-HSCT withposttransplant cyclophosphamide (PT/Cy-haplo) and compared it with patients allografted with HLA-matched donors. PlasmaCMV DNA load was monitored by real-time PCR and enumeration of CMV-specific IFN-γ-producing CD8+ and CD4+T cells was performed by flow cytometry for intracellular cytokine staining at days +30, +60, +90, and +180 aftertransplantation. CMV DNAemia developed in 62 patients, occurring with comparable frequency in PT/Cy-haplo and MRD/MUD recipients (P =0.14). There were no significant differences across groups in the number of patients either displayingdetectable CMV-specific CD8+ and CD4+ T-cell responses or acquiring CMV-specific T-cell levels conferring protectionagainst subsequent infection. CMV-specific T-cell counts were comparable between groups at most time points examined,irrespective of whether CMV DNAemia occurred or not prior to monitoring. Collectively the data suggest that PT/Cy-haplorecipients may reconstitute CMV-specific T-cell immunity to the same extent as patients undergoing HLA-matched allo-HSCT.
%~